Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Autor: Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Mark Jones, Deanna Kornacki, Kang Sun, Hagop Kantarjian, for the COMFORT-I investigators

Publikováno v: Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-14 (2017)

Abstract Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. The primary and planned 3-year analyses of COMFORT-I

Externí odkaz: https://doaj.org/article/7414efd9cbe24affac81f3167f71f9d0

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Autor: Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, Victor Sandor, Hagop Kantarjian

Publikováno v: Haematologica, Vol 100, Iss 4 (2015)

In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to place

Externí odkaz: https://doaj.org/article/7b14e5f72f2a48e1a0c3dbba240ffc5c

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

Autor: Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Susan Erickson-Viitanen, William Sun, Victor Sandor, Hagop M. Kantarjian

Publikováno v: Haematologica, Vol 98, Iss 12 (2013)

COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with intermediate-2 or high-risk myelofibrosis. This analysis of COMFORT-I describes the long-term efficacy a

Externí odkaz: https://doaj.org/article/eb6fdd88d68b49a881699bb335455fab

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Autor: John Mascarenhas, Heidi E. Kosiorek, Josef T. Prchal, Alessandro Rambaldi, Dmitriy Berenzon, Abdulraheem Yacoub, Claire N. Harrison, Mary Frances McMullin, Alessandro M. Vannucchi, Joanne Ewing, Casey L. O'Connell, Jean-Jacques Kiladjian, Adam J. Mead, Elliott F. Winton, David S. Leibowitz, Valerio De Stefano, Murat O. Arcasoy, Craig M. Kessler, Rosalind Catchatourian, Damiano Rondelli, Richard T. Silver, Andrea Bacigalupo, Arnon Nagler, Marina Kremyanskaya, Max F. Levine, Juan E. Arango Ossa, Erin McGovern, Lonette Sandy, Mohamad E. Salama, Vesna Najfeld, Joseph Tripodi, Noushin Farnoud, Alexander V. Penson, Rona Singer Weinberg, Leah Price, Judith D. Goldberg, Tiziano Barbui, Roberto Marchioli, Gianni Tognoni, Raajit K. Rampal, Ruben A. Mesa, Amylou C. Dueck, Ronald Hoffman

Publikováno v: Mascarenhas, J, Kosiorek, H E, Prchal, J T, Rambaldi, A, Berenzon, D, Yacoub, A, Harrison, C N, McMullin, M F F, Vannucchi, A M, Ewing, J, O'Connell, C L, Kiladjian, J-J, Mead, A J, Winton, E F, Leibowitz, D S, De Stefano, V, Arcasoy, M O, Kessler, C M, Catchatourian, R, Rondelli, D, Silver, R T, Bacigalupo, A, Nagler, A, Kremyanskaya, M, Levine, M F, Arango Ossa, J E, McGovern, E M, Sandy, L, Salama, M E, Najfeld, V, Tripodi, J, Farnoud, N, Penson, A V, Weinberg, R S, Price, L, Goldberg, J D, Barbui, T, Marchioli, R, Tognoni, G, Rampal, R K, Mesa, R A, Dueck, A C & Hoffman, R 2022, ' A Randomized, Phase 3, Trial of Interferon-α versus Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia ', Blood . https://doi.org/10.1182/blood.2021012743

The goal of therapy for essential thrombocythemia (ET) and polycythemia vera (PV) patients is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and interferon-α (IFN-α) are the most frequently used cytoreductive options for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a60a8c97e7746d771d21615b282b0fc
https://pubmed.ncbi.nlm.nih.gov/35007321

Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia

Autor: Leonard T. Heffner, Sheldon Bolds, Asim Pati, Amy A. Langston, Morgan L. McLemore, Stephanie Debragga, Prachi Karkhanis, Robert K. Stuart, Anand Jillella, Michael R. Grunwald, Manila Gaddh, Vamsi Kota, Martha Arellano, Jorge E. Cortes, Chao Zhang, Catherine R. Caprara, Kathryn Sarah Simon, Mohamed M. El Geneidy, Shruthi H. Krishnamurthy, Jonathan M. Gerber, Elliott F. Winton, Jose Tongol, Asad Bashey

Publikováno v: JCO oncology practice. 17(4)

PURPOSE: Acute promyelocytic leukemia (APL) is a curable leukemia with > 90% survival in clinical trials. Population-based studies from Sweden and US SEER data have shown long-term survival rates of 62% and 65.7%, with the lower rate being from a hig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1183633f9b11ca0cf602808244634a8c
https://pubmed.ncbi.nlm.nih.gov/33125295